Neuronal Exosomes Reveal Alzheimer'S Disease Biomarkers In Down Syndrome
Department
neurobiology
Document Type
Article
Abstract
Introduction Individuals with Down syndrome (DS) exhibit Alzheimer's disease (AD) neuropathology and dementia early in life. Blood biomarkers of AD neuropathology would be valuable, as non-AD intellectual disabilities of DS and AD dementia overlap clinically. We hypothesized that elevations of amyloid β (Aβ) peptides and phosphorylated-tau in neuronal exosomes may document preclinical AD. Methods AD neuropathogenic proteins Aβ1–42, P-T181-tau, and P-S396-tau were quantified by enzyme-linked immunosorbent assays in extracts of neuronal exosomes purified from blood of individuals with DS and age-matched controls. Results Neuronal exosome levels of Aβ1–42, P-T181-tau, and P-S396-tau were significantly elevated in individuals with DS compared with age-matched controls at all ages beginning in childhood. No significant gender differences were observed. Discussion These early increases in Aβ1–42, P-T181-tau, and P-S396-tau in individuals with DS may provide a basis for early intervention as targeted treatments become available.
Publication Date
5-1-2017
Publication Title
Alzheimer's and Dementia
ISSN
15525260
Volume
13
Issue
5
First Page
541
Last Page
549
Digital Object Identifier (DOI)
10.1016/j.jalz.2016.08.012
Recommended Citation
Hamlett, Eric D.; Goetzl, Edward J.; Ledreux, Aurélie; Vasilevko, Vitaly; Boger, Heather A.; LaRosa, Angela; Clark, David; Carroll, Steven L.; Carmona-Iragui, MarÃa; Fortea, Juan; Mufson, Elliott J.; Sabbagh, Marwan; Mohammed, Abdul H.; Hartley, Dean; Doran, Eric; Lott, Ira T.; and Granholm, Ann Charlotte, "Neuronal Exosomes Reveal Alzheimer'S Disease Biomarkers In Down Syndrome" (2017). Translational Neuroscience. 337.
https://scholar.barrowneuro.org/neurobiology/337